Biotech.. NRT may be worth entering on the list too, been trading in the 'low risk' 9.5-10c entry price range for a month now.
TLX Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
I88 Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”
